Key result
IV erenumab shows non-inferiority to placebo for total exercise time in stable angina.
Why the study?
The relative importance of the CGRP receptor pathway during myocardial ischemia has not been established.
Does erenumab reduce total exercise time compared to placebo in patients with stable angina due to documented coronary artery disease?
Comparison
Single IV infusion of erenumab 140 mg vs placebo
Design
Randomized double-blind placebo-controlled study
Follow-up
12 weeks
Authors
Loading...
Erenumab noninferior to placebo on exercise tolerance in stable angina; confirms CGRP inhibition does not worsen ischemia in high-risk CAD patients.
RCT (n=88)
Double-blind
Randomized
Does erenumab reduce total exercise time compared to placebo in patients with stable angina due to documented coronary artery disease?
Mean Difference: -11 (95% CI -44.9–22.9)
Absolute Event Rate: -2.9% vs 8.1%
Erenumab does not adversely affect exercise time in patients with stable angina, suggesting that CGRP receptor inhibition does not worsen myocardial ischemia.
Depré et al. (2018) conducted an RCT in Stable angina due to documented coronary artery disease (n=88). Erenumab vs. Placebo was evaluated on Change from baseline in exercise duration as measured by total exercise time (TET) (MD -11.0 seconds, 95% CI -44.9 to 22.9). A single IV infusion of erenumab was non-inferior to placebo for change in total exercise time in patients with stable angina (mean difference -11.0 seconds; 90% CI -44.9 to 22.9).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: